drugset
drugset / Trial / NCT05462496

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

NCT05462496 ↗

Phase 2 Recruiting 25 enrolled Icahn School of Medicine at Mount Sinai
NaSingle-groupOpen-labelTreatment

Summary

A multi-institutional, single arm pilot study of antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.

Timeline

Start
2023-03-16
Primary completion
2027-08
Completion
2028-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciprofloxacin Small molecule 500 mg Oral
Subject Metronidazole Small molecule 500 mg Oral
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Background Irinotecan Small molecule 150 mg/m2 Intravenous
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

malignant pancreatic neoplasm